Using data from a randomized, treat-to-target, non-inferiority trial—BEGIN YOUNG 1—annual costs with degludec versus IDet in children and adolescents aged 1–17 years with T1D were estimated, as costs of these insulins and hyperglycemia with ketosis events. The gene discussed is INS; the disease is Hyperglycemia.